Trial Profile
A Single center Efficacy and Safety Study of Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B cell hematologic malignancies included acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma(NHL), multiple myeloma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 31 Oct 2017
Price :
$35
*
At a glance
- Drugs Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 31 Oct 2017 New trial record